Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivir transfers HIV drug license to Beijing Mefuvir
Under the new terms for MIV-310, Mefuvir will finance the clinical development towards registration in Asia. Mefuvir has the marketing rights in Asia except Japan. Medivir retains the
Under the new terms for MIV-310, Mefuvir will finance the clinical development towards registration in Asia. Mefuvir has the marketing rights in Asia except Japan. Medivir retains the
As a result of the expanded CE Mark, the Taxus Liberte stent system in the EU is indicated for treatment of de novo and restenotic lesions or total
The company expects to initiate a limited launch of RenalGuard in the first quarter of 2008 in Italy, targeting early adoptors who recognize the benefits of utilizing the
Subject to the satisfaction of customary closing conditions, the transaction is expected to close on or about December 24, 2007. Net proceeds from the transaction will be used
Under the terms of the combination agreement entered into on October 17, 2007 all conditions to Galenica’s obligation to complete the transaction will be deemed to have been
Mr. Smith has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as president and CEO of Ino Therapeutics, a specialty
The company does not expect to record Biomateriali revenue for the balance of 2007. It is expected that this acquisition will be dilutive in 2008. The Biomateriali acquisition
Similar applications for a parallel European Phase III trial are planned to be submitted to European regulatory agencies. Diamyd Medical anticipates that two successful Phase III studies, each
The filing is based on data from the 682 patient Phase III VISTA (Velcade as initial standard therapy in multiple myeloma: assessment with melphalan and prednisone) trial, one
The initial Phase I clinical trial of LX1032 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers. This study is designed to evaluate the